CLOUDR 2025 Mid-term Performance Briefing: Operating Cash Flow Turns Positive for the First Time, P2M Business Grows by 142.1%

On August 27th, CLOUDR released its semi-annual performance: same-caliber revenue of 890 million yuan, a year-on-year increase of 20.3%; adjusted gross margin increased by 29.3 percentage points year-on-year to 49.9%, and net loss narrowed by 23.3%; operating cash flow turned positive historically, with a net inflow of 28.65 million yuan (compared to a net outflow of 195 million yuan in the same period last year). Revenue from P2M solutions was 260 million yuan with profitability, a year-on-year increase of 142.1%; six core products have been launched, and eight new products are queued for launch. The AI dual model (ClouD GPT/DTx) has completed the data-monetization closed loop, and the gestational diabetes solution has been published in an international journal; the company's SaaS has covered over 2,700 hospitals and nearly 270,000 pharmacies. Management stated that they will accelerate the commercialization of P2M and consolidate their leading position in chronic disease digitalization